KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to -$1.3 billion.

  • Rigel Pharmaceuticals' Retained Earnings rose 806.75% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 806.75%. This contributed to the annual value of -$1.4 billion for FY2024, which is 124.22% up from last year.
  • Rigel Pharmaceuticals' Retained Earnings amounted to -$1.3 billion in Q3 2025, which was up 806.75% from -$1.3 billion recorded in Q2 2025.
  • Rigel Pharmaceuticals' Retained Earnings' 5-year high stood at -$1.3 billion during Q1 2021, with a 5-year trough of -$1.4 billion in Q2 2024.
  • For the 5-year period, Rigel Pharmaceuticals' Retained Earnings averaged around -$1.4 billion, with its median value being -$1.4 billion (2022).
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 670.04% in 2022, then surged by 806.75% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Retained Earnings stood at -$1.3 billion in 2021, then decreased by 4.42% to -$1.4 billion in 2022, then dropped by 1.81% to -$1.4 billion in 2023, then rose by 1.24% to -$1.4 billion in 2024, then rose by 7.12% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.4 billion during Q1 2025.